Literature DB >> 15803373

Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.

Jing Han1, Liming Yang, Raj K Puri.   

Abstract

IL-13 cytotoxin comprised of IL-13 and a mutated form of Pseudomonas exotoxin (fusion protein termed IL-13-PE38QQR) has been shown to inhibit protein synthesis leading to necrotic and apoptotic cell death in glioblastoma cells that express high levels of interleukin-13 receptors (IL-13R). To identify target genes of cell death and other cellular genes with IL-13 receptors in glioblastoma cells, we utilized the cDNA microarrays to analyze global gene expression profiles after IL-13 cytotoxin and IL-13 treatment. IL-13 cytotoxin mediated cytotoxicity to U251 cells in a dose-dependent manner. Hierarchical cluster analysis of differentially expressed genes in U251 glioma cells at different time points after IL-13 cytotoxin treatment showed three major groups, each representing a specific expression pattern. Randomly selected differentially expressed genes from each group were confirmed by RT-PCR analysis. Most down-regulated genes belong to cell adhesion, motility, angiogenesis, DNA repair, and metabolic pathways. While up-regulated genes belong to cell cycle arrest, apoptosis, signaling and various metabolic pathways. Unexpectedly, at early time points, both IL-13 and IL-13 cytotoxin induced several genes belonging to different pathways most notably IL-8, DIO2, END1, and ALDH1A3 indicating that these genes are early response genes and their products may be associated with IL-13R. In addition, IL-13 cytotoxin induced IL-13Ralpha2 mRNA expression during the treatment in glioma cells. Our results indicate that novel cellular genes are involved with IL-13 receptors and that IL-13 cytotoxin induced cell death involves various target genes in human glioblastoma cells. On going studies will determine the role of associated genes and their products in the IL-13R functions in glioma cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15803373     DOI: 10.1007/s11060-004-3119-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  54 in total

Review 1.  Options available--from start to finish--for obtaining expression data by microarray.

Authors:  D D Bowtell
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

Review 2.  The cell biology of thrombospondin-1.

Authors:  H Chen; M E Herndon; J Lawler
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

3.  The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway.

Authors:  K Kawakami; J Taguchi; T Murata; R K Puri
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

4.  Quantitative monitoring of gene expression patterns with a complementary DNA microarray.

Authors:  M Schena; D Shalon; R W Davis; P O Brown
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

Review 5.  Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review).

Authors:  T Murata; N I Obiri; R K Puri
Journal:  Int J Mol Med       Date:  1998-03       Impact factor: 4.101

Review 6.  Cytokine receptor as a sensitizer for targeted cancer therapy.

Authors:  Koji Kawakami; Mariko Kawakami; Raj K Puri
Journal:  Anticancer Drugs       Date:  2002-08       Impact factor: 2.248

Review 7.  Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.

Authors:  Mariko Kawakami; Koji Kawakami; Raj K Puri
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

Review 8.  Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.

Authors:  Michael Weaver; Douglas W Laske
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

9.  Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.

Authors:  S R Husain; R K Puri
Journal:  Blood       Date:  2000-06-01       Impact factor: 25.476

10.  Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).

Authors:  R K Puri; P Leland; N I Obiri; S R Husain; R J Kreitman; G P Haas; I Pastan; W Debinski
Journal:  Blood       Date:  1996-05-15       Impact factor: 25.476

View more
  5 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

Review 2.  Physiological insights into all-trans-retinoic acid biosynthesis.

Authors:  Joseph L Napoli
Journal:  Biochim Biophys Acta       Date:  2011-05-19

Review 3.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 4.  Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily.

Authors:  Satori A Marchitti; Chad Brocker; Dimitrios Stagos; Vasilis Vasiliou
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-06       Impact factor: 4.481

5.  Identification and characterization of alternative exon usage linked glioblastoma multiforme survival.

Authors:  Ahmed Sadeque; Nicola Vl Serão; Bruce R Southey; Kristin R Delfino; Sandra L Rodriguez-Zas
Journal:  BMC Med Genomics       Date:  2012-12-04       Impact factor: 3.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.